A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy (Start up)
Clinical Trial Grant
Administered By
Pediatrics, Pulmonary and Sleep Medicine
Awarded By
Pfizer, Inc.
Start Date
May 8, 2025
End Date
December 31, 2040
Administered By
Pediatrics, Pulmonary and Sleep Medicine
Awarded By
Pfizer, Inc.
Start Date
May 8, 2025
End Date
December 31, 2040